LINKS
CONTACT & CONNECT

Headquarters:

19950 W Country Club Drive
7th Floor

Aventura, FL 33180

International Offices:

Germany

info@ipdanalytics.com

+1 (305) 662-8515

  • LinkedIn Social Icon
  • Twitter Social Icon
Asset 211.png

© 2019 by IPD Analytics | Privacy Policy

IPD'S DRUG & CLINICAL REVIEW

THE PREMIER PODCAST FOR DRUG INTELLIGENCE & MANAGEMENT STRATEGY

SAMPLE EPISODES

INFECTIOUS DISEASES: HIV AND HEPATITIS C
MANAGEMENT STRATEGY

Our Executive Clinical Pharmacy team discusses the drug pipeline and market landscape for HIV and Hepatitis C, including:

  • HIV:

    • Integrase Strand Transfer Inhibitors (INSTIs) 

    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 

    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

    • Protease Inhibitors

    • Two and Three Tablet Regimens 

    • Single Tablet Regimens 

    • New Guidelines for Recommended Regimens for First-line ART 

    • HIV Pipeline Drugs 

    • 505(b)(2)s 

    • Current Successful Management Strategies

    • Truvada and Descovy for PrEP 

  • Hepatitis C:

    • Recent Key Events 

    • Management Strategies 

 

SEE MORE

IMMUNE GLOBULIN SHORTAGE FALL 2019

Our Executive Clinical Pharmacy team discusses the Immune Globulin (IG) shortage affecting hospitals, infusion centers, specialty pharmacies, and payers across the United States, including:

  • Severity

  • Causes of the shortage

  • Manufacturer comments

  • Treatment options - clinical efficacy and differentiation

  • Patient prioritization tactics

  • Switching and substitution

  • Payer impacts

  • Potential for resolution

SEE MORE

MANUFACTURER LIFE-CYCLE MANAGEMENT STRATEGIES

Our Executive Clinical Pharmacy team explains manufacturer life-cycle management strategies, including specific examples of successes and failures, including:

  • Additional indications

  • New formulations

  • Next generation products

  • Different strengths

  • Bundling

  • Brand over generic strategies

  • Reimbursement incentives and coding strategies

  • Distribution channels

  • Co-pay assistance programs

  • Strategic partnerships

  • Authorized generics

SEE MORE 

BIOLOGICS HOT TOPICS OCTOBER 2019

Our Executive Clinical Pharmacy team takes you through the hot topics trending in biosimilars in late July 2019, including: 

  • Avastin/Herceptin

  • Rituxan 

  • Humira/ Enbrel 

SEE MORE

UNDERSTANDING AUTHORIZED GENERICS 

Our Executive Clinical Pharmacy Team discusses Authorized Generics (AGs) and their impacts across the marketplace, including:

  • Differences between AGs and traditional generic drugs

  • Manufacturer motivations for launching AGs

  • Examples of current AGs, positioning tactics, and potential launches

  • Impact on price erosion and uptake

  • Forecasting implications

  • Payer considerations for various lines of business

  • And more
     

SEE MORE

AN INSIDE LOOK AT FORMULARY MANAGEMENT AND P&T COMMITTEES

IPD experts take you through the basics of how P&T Committees work to plan their formularies, including:

  • P&T Committee goals, members, and purpose

  • Clinical and financial reviews

  • Formulary tiering

  • Payer formulary planning trends

  • Manufacturer timing and communication strategies for formulary inclusion

SEE MORE

SKINNY LABELS AND OFF-LABEL UTILIZATION

Our clinical pharmacists and and former Federal Circuit Clerks take you through the basics of skinny labels and off-label drug use, including:

  • Definition and motivations behind skinny labels

  • Examples of skinny labels in the market

  • Small molecule drugs vs. biosimilars

  • Payer, provider, manufacturer, retailer, and patient implications

  • Off-label use regulation

 

SEE MORE

Find out how to access all of our podcast episodes!